Lys Therapeutics
  • Science
  • Who we are
    • Management and team
    • Board of Directors
    • Scientific Advisory Board
    • Awards
    • Other partners
  • Pipeline
  • Newsroom
    • Press Releases
    • Congresses & events
  • Career
  • Contact
  • Menu Menu

Lys Therapeutics secures an additional €2.15 million in funding as a winner of the i-Nov innovation competition organized by the French government to accelerate the clinical development of its drug candidate LYS241

Press Releases
Read more
September 24, 2024
https://lystherapeutics.com/wp-content/uploads/2024/09/capture-decran-2024-09-23-234709.png 1256 1792 lys https://lystherapeutics.com/wp-content/uploads/2022/05/logo-lys-therapeuticsv3.png lys2024-09-24 08:00:312024-09-24 09:04:11Lys Therapeutics secures an additional €2.15 million in funding as a winner of the i-Nov innovation competition organized by the French government to accelerate the clinical development of its drug candidate LYS241

Lys Therapeutics Announces Significant Scientific Advances in Neurodegenerative and Neurovascular Diseases

Press Releases
Read more
May 30, 2024
https://lystherapeutics.com/wp-content/uploads/2024/05/capture-decran-2024-05-30-194554.png 1219 2136 lys https://lystherapeutics.com/wp-content/uploads/2022/05/logo-lys-therapeuticsv3.png lys2024-05-30 08:47:012024-06-01 15:16:44Lys Therapeutics Announces Significant Scientific Advances in Neurodegenerative and Neurovascular Diseases

Lys Therapeutics announces that Michel Vounatsos is appointed chairman of its Board of Directors

Press Releases
Read more
March 22, 2024
https://lystherapeutics.com/wp-content/uploads/2024/03/capture-decran-2024-03-22-145306.png 481 1132 lys https://lystherapeutics.com/wp-content/uploads/2022/05/logo-lys-therapeuticsv3.png lys2024-03-22 13:52:112024-03-22 13:54:48Lys Therapeutics announces that Michel Vounatsos is appointed chairman of its Board of Directors

Lys Therapeutics announces €2 million grant from Bpifrance

Press Releases
Read more
November 14, 2023
https://lystherapeutics.com/wp-content/uploads/2023/11/capture-decran-2023-11-14-095710.png 817 1963 lys https://lystherapeutics.com/wp-content/uploads/2022/05/logo-lys-therapeuticsv3.png lys2023-11-14 08:30:152023-11-16 15:54:06Lys Therapeutics announces €2 million grant from Bpifrance

Lys Therapeutics announces positive preclinical results for its drug candidate in synergy with gold standard treatments for ischemic stroke

Press Releases
Read more
September 26, 2023
https://lystherapeutics.com/wp-content/uploads/2023/09/capture-decran-2023-09-28-140128.png 528 1036 lys https://lystherapeutics.com/wp-content/uploads/2022/05/logo-lys-therapeuticsv3.png lys2023-09-26 09:00:432023-09-28 12:06:44Lys Therapeutics announces positive preclinical results for its drug candidate in synergy with gold standard treatments for ischemic stroke

Lys Therapeutics presents new preclinical data in Parkinson’s at the « International Congress of Parkinson’s Disease and Movement Disorders® »

Press Releases
Read more
August 18, 2023
https://lystherapeutics.com/wp-content/uploads/2023/08/capture-decran-2023-08-31-142110.png 421 898 lys https://lystherapeutics.com/wp-content/uploads/2022/05/logo-lys-therapeuticsv3.png lys2023-08-18 08:00:132023-08-31 12:22:23Lys Therapeutics presents new preclinical data in Parkinson’s at the « International Congress of Parkinson’s Disease and Movement Disorders® »

Lys Therapeutics secures funding from The Michael J. Fox Foundation to accelerate the development of its drug candidate in Parkinson’s disease

Press Releases
Read more
March 15, 2023
https://lystherapeutics.com/wp-content/uploads/2023/09/capture-decran-2023-08-31-142315.png 619 1193 lys https://lystherapeutics.com/wp-content/uploads/2022/05/logo-lys-therapeuticsv3.png lys2023-03-15 09:00:002023-09-19 13:22:03Lys Therapeutics secures funding from The Michael J. Fox Foundation to accelerate the development of its drug candidate in Parkinson’s disease

Lys Therapeutics announces a seed round of 5.5 million euros to prepare future clinical studies for its first-in-class monoclonal antibody targeting neurovascular and neurodegenerative disorders

Press Releases
Read more
November 14, 2022
https://lystherapeutics.com/wp-content/uploads/2023/08/capture-decran-2023-08-31-142344.png 425 902 lys https://lystherapeutics.com/wp-content/uploads/2022/05/logo-lys-therapeuticsv3.png lys2022-11-14 16:43:082024-06-19 13:59:22Lys Therapeutics announces a seed round of 5.5 million euros to prepare future clinical studies for its first-in-class monoclonal antibody targeting neurovascular and neurodegenerative disorders

Nine startups are working on brain pathologies together with the Blood and Brain Institute BB@C in Normandy

Press Releases
Read more
March 14, 2022
https://lystherapeutics.com/wp-content/uploads/2023/08/capture-decran-2023-08-31-142448.png 402 895 lys https://lystherapeutics.com/wp-content/uploads/2022/05/logo-lys-therapeuticsv3.png lys2022-03-14 09:00:192023-09-19 13:05:35Nine startups are working on brain pathologies together with the Blood and Brain Institute BB@C in Normandy

Lys Therapeutics and Inserm Transfert sign a three-year agreement for joint research on stroke and multiple sclerosis

Press Releases
Read more
March 3, 2022
https://lystherapeutics.com/wp-content/uploads/2023/09/capture-decran-2023-08-31-142527.png 644 1200 lys https://lystherapeutics.com/wp-content/uploads/2022/05/logo-lys-therapeuticsv3.png lys2022-03-03 14:28:082023-09-19 13:23:22Lys Therapeutics and Inserm Transfert sign a three-year agreement for joint research on stroke and multiple sclerosis

Lys Therapeutics and the BB@C Institute to hold a scientific conference in support of World Stroke Day

Press Releases
Read more
October 22, 2021
https://lystherapeutics.com/wp-content/uploads/2023/08/capture-decran-2023-08-31-142624.png 275 901 lys https://lystherapeutics.com/wp-content/uploads/2022/05/logo-lys-therapeuticsv3.png lys2021-10-22 08:58:072023-09-19 13:00:56Lys Therapeutics and the BB@C Institute to hold a scientific conference in support of World Stroke Day

Lys Therapeutics, Grand Prize winner of the i-Lab innovation competition, accelerates its research on its lead drug-candidate Glunozumab

Press Releases
Read more
October 15, 2021
https://lystherapeutics.com/wp-content/uploads/2023/09/capture-decran-2023-08-31-142556.png 1106 2049 lys https://lystherapeutics.com/wp-content/uploads/2022/05/logo-lys-therapeuticsv3.png lys2021-10-15 09:13:432023-09-19 13:14:28Lys Therapeutics, Grand Prize winner of the i-Lab innovation competition, accelerates its research on its lead drug-candidate Glunozumab
© Copyright Lys Therapeutics
  • LinkedIn
  • Mentions légales
Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Accept settingsHide notification onlyParameters

Cookie and Privacy Settings



How we use cookies

We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.

Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.

We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.

We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.

Google Analytics Cookies

These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.

If you do not want that we track your visit to our site you can disable tracking in your browser here:

Other external services

We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Google reCaptcha Settings:

Vimeo and Youtube video embeds:

Other cookies

The following cookies are also needed - You can choose if you want to allow them:

Accept settingsHide notification only